Kala Bio Inc (NAS:KALA)
$ 6.865 0.0486 (0.71%) Market Cap: 19.34 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 51/100

Q2 2021 Kala Pharmaceuticals Inc Earnings Call Transcript

Aug 05, 2021 / 12:00PM GMT
Release Date Price: $159 (-5.07%)
Operator

Good morning, and welcome to Kala Pharmaceuticals Second Quarter 2021 Financial Results Conference Call. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to turn the conference over to Niranjan Kameswaran, Senior Vice President of Strategy of Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran
Kala Pharmaceuticals, Inc. - SVP of Strategy

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman, President and Chief Executive Officer; Todd Bazemore, Chief Operating Officer; Mary Reumuth, Chief Financial Officer; and Kim Brazzell, our Chief Medical Officer, will also be joining us for the Q&A portion of today's call.

Today's call is being webcast live. The webcast link can be found in the Investors & Media section of our website at www.kalarx.com. During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot